Eli Lilly and Bayer publicly criticised Germany’s recent surge in spending on new medicines, saying the cost increase threatens patient access and strains public budgets. The two firms argued that higher prices reflect genuine innovation and that policymakers should focus on value‑based assessments rather than blanket cuts. They warned insurers could face higher premiums. Their comments echo a broader industry pushback against price‑control measures.

German health officials have defended the rise, citing an ageing population and a wave of breakthrough therapies for cancer and rare diseases. They claim the additional outlay, estimated in the low‑hundreds of millions of euros, is necessary to keep the country at the forefront of medical advancement. Critics warn the spending could outpace inflation and crowd out other health priorities.

Analysts see the dispute as a bellwether for Europe’s drug‑price debate, noting that US lawmakers are also targeting price‑reducing legislation. If Germany curtails reimbursements, Eli Lilly and Bayer could shift focus to markets with more favourable pricing frameworks, potentially reshaping revenue streams. Both firms continue lobbying EU regulators for harmonised pricing rules. The standoff underscores how government budgets and pharma profitability are increasingly intertwined.